Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Core Insights - Cardiol Therapeutics has completed the MAvERIC Phase II study for recurrent pericarditis, with results to be presented at the American Heart Association Scientific Sessions 2024 on November 18, 2024 [2][3][4] Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease [7][8] - The company's lead drug candidate, CardiolRx™, is an oral solution of cannabidiol aimed at treating heart disease by inhibiting inflammation and fibrosis [7][8] Study Details - The MAvERIC-Pilot study involved 27 adult participants with symptomatic recurrent pericarditis, assessing the efficacy of CardiolRx™ over an 8-week treatment period followed by an 18-week extension [5] - The primary endpoint was the change in patient-reported pericarditis pain from baseline to 8 weeks, with secondary endpoints including pain scores at 26 weeks and freedom from recurrence during the extension period [5] Clinical Significance - Recurrent pericarditis affects approximately 38,000 patients annually in the U.S., with significant impacts on quality of life and healthcare costs [6] - The only FDA-approved therapy for this condition is costly and primarily used as a third-line treatment, highlighting the need for more accessible options like CardiolRx™ [6] Future Plans - The company anticipates that the full clinical results from the MAvERIC-Pilot study will support plans to advance to a Phase III trial of CardiolRx™ [4][11] - Cardiol Therapeutics is also developing CRD-38, a novel subcutaneous formulation intended for use in heart failure, addressing a major healthcare challenge with significant costs [9]